Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exosome multivalent vaccine - Capricor Therapeutics

Next Previous
Drug Profile

Exosome multivalent vaccine - Capricor Therapeutics

Alternative Names: Exosome display vaccine; Exosome-SARS-CoV-2 Display Vaccine; StealthX™ vaccine

Latest Information Update: 26 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Capricor Therapeutics
  • Class COVID-19 vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - COVID 2019 infections

Highest Development Phases

  • Preclinical COVID 2019 infections

Most Recent Events

  • 13 May 2025 Preclinical development is ongoing in COVID-2019-infections (Prevention) in USA (IM)
  • 13 May 2025 National Institute of Allergy and Infectious Diseases plans a phase I trial for COVID-2019 infections (Prevention) (IM), in the third quarter of 2025
  • 19 Mar 2025 The National Institute of Allergy and Infectious Diseases (NIAID) announces intention to receive regulatory approval for the clinical trial of exosome multivalent vaccine in the second quarter of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top